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Advanced glycation end products (AGEs) consist of heterogenous group of macroprotein derivatives, which are
formed by non-enzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids,
and whose process has progressed at an accelerated rate under diabetes. Non-enzymatic glycation and cross-linking
of protein alter its structural integrity and function, contributing to the aging of macromolecules. Furthermore,
engagement of receptor for AGEs (RAGE) with AGEs elicits oxidative stress generation and subsequently evokes
proliferative, inflammatory, and fibrotic reactions in a variety of cells. Indeed, accumulating evidence has suggested
the active involvement of accumulation of AGEs in diabetes-associated disorders such as diabetic microangiopathy,
atherosclerotic cardiovascular diseases, Alzheimer’s disease and osteoporosis. Glucagon-like peptide-1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) are incretins, gut hormones secreted from the intestine in response
to food intake, both of which augment glucose-induced insulin release, suppress glucagon secretion, and slow gastric
emptying. Since GLP-1 and GIP are rapidly degraded and inactivated by dipeptidyl peptidase-4 (DPP-4), inhibition of
DPP-4 and/or DPP-4-resistant GLP-1 analogues have been proposed as a potential target for the treatment of diabetes.
Recently, DPP-4 has been shown to cleave multiple peptides, and blockade of DPP-4 could exert diverse biological
actions in GLP-1- or GIP-independent manner. This article summarizes the crosstalk between AGEs-RAGE axis and
DPP-4-incretin system in the development and progression of diabetes-associated disorders and its therapeutic
intervention, especially focusing on diabetic vascular complications.
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According to the recent report of Diabetes Atlas, about
380 million people have diabetes, and the number is still
increasing in almost every country, especially in Asian
areas [1]. Diabetic micro- and macroangiopathy are dev-
astating vascular complications of diabetes. From the
standpoint of patients’ quality of life, diabetes is in a
sense one of the cardiovascular diseases. Indeed, diabetic
nephropathy and retinopathy are one of the leading
causes of end-stage renal failure and acquired blindness,* Correspondence: shoichi@med.kurume-u.ac.jp
1Department of Pathophysiology and Therapeutics of Diabetic Vascular
Complications, Kurume University School of Medicine, 67 Asahi-machi, Kurume
830-0011, Japan
Full list of author information is available at the end of the article
© 2015 Yamagishi et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.respectively, which in concert with neuropathy could
account for disabilities in patients with diabetes [1-3].
Atherosclerotic cardiovascular diseases (CVD) account
for about 60% of death in diabetic subjects [4]. Further-
more, even after adjusting several risk factors, including
systolic blood pressure, lipid levels, C-reactive protein
and fibrinogen values, socioeconomic status, or estimated
glomerular filtration rate, hazard ratios among diabetic
patients as compared with non-diabetic people were 1.8
for death from any cause, 2.3 from CVD, 1.7 from non-
CVD, and 1.25 from several cancers [4]. On the other
hand, the association of diabetes with mortality was
considerably reduced after adjusting for fasting glucose
or glycated hemoglobin levels. At fasting glucose levels
above 100 mg/dl, hazard ratio of vascular, non-vasculartral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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increments of 18 mg/dl, were 1.13, 1.10 and 1.05, respect-
ively [4]. Along with this, life expectancy is reduced by
more than 20 years in middle-aged people of type 1
diabetes and by up to 10 years in middle aged-type 2
diabetic patients compared with non-diabetic subjects
[4-7]. 40-years old diabetic subjects without known CVD
at the time of enrollment died about 6.3 years younger
than non-diabetic subjects [4]. As a result, average life
span of diabetic patients is about 10-15-years shorter than
that of non-diabetic subjects. Moreover, the increased risk
for Alzheimer’s disease and osteoporosis is also observed
in diabetic patients [8,9]. These observations indicate that
the risk of aging-related disorders and premature death is
high in diabetic subjects and that cumulative hypergly-
cemic exposure might be directly involved in the high
mortality rate in patients with diabetes. Since accumulation
of advanced glycation end products (AGEs) could reflect
cumulative historical diabetic exposure, and thereby, play a
role in various diabetes and/or aging-associated disorders
[2,8,9], blockade of harmful effects of AGEs might be a
novel therapeutic target for organ protection in diabetes.
Further, inhibition of dipeptidyl peptidase-4 (DPP-4), a
responsible enzyme that mainly degrades incretins such as
glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP), has been shown not only
to improve glycemic control, but also to exert diverse
beneficial actions in GLP-1- or GIP-independent manner
[10]. So, this article summarizes the crosstalk between
AGEs-receptor for AGEs (RAGE) axis and DPP-4-incretin
system in the development and progression of diabetes-
associated disorders and its therapeutic intervention, espe-
cially focusing on diabetic vascular complications. In the
present review, literature searches were undertaken in
Medline by the PubMed interface. Non-English language
articles were excluded. Key words ((glycation or RAGE)
and (DPP-4 or GLP-1 or GIP or incretins) have been used
to select the articles.
Metabolic memory, legacy effect and hyperglycemic curse
The Diabetes Control and Complications Trial-Epidemi-
ology of Diabetes Interventions and Complications (DCCT-
EDIC) Research, has revealed that the reduction in the risk
of progressive retinopathy and nephropathy resulting from
intensive therapy in patients with type 1 diabetes persists
for at least several years after the DCCT trial, despite
increasing hyperglycemia [11,12]. Recently, intensive dia-
betes treatment has been shown to yield durable retinal
and renal benefits that persist for at least 18 years after its
application [13,14], and the prevalence and incidence of
diabetic peripheral neuropathy and cardiovascular auto-
nomic neuropathy have remained significantly lower in the
DCCT intensive therapy group compared with the DCCT
conventional therapy group through EDIC year 13-14 [15].In addition, intensive therapy during the DCCT resulted in
decreased progression of intima-media thickness (IMT)
and subsequently reduced the risk of nonfatal myocardial
infarction, stroke, or death from cardiovascular disease by
57% 11 years after the end of the trials [16,17]. The major
adverse effect of intensive therapy was a threefold increased
risk of hypoglycemia, which was not associated with a
decline in cognitive function or quality of life [18].
Compared with intensive therapy group subjects who
remained weight stable during DCCT, excess gainers main-
tained greater body mass index and waist circumference,
had greater IMT of carotid artery, and trended toward
greater coronary artery calcium scores [19]. Increasing
frequency of a family history of diabetes mellitus, hyper-
tension, and hyperlipidemia was associated with greater
IMT in patients of intensive but not conventional treat-
ment group [19]. These observations suggest that genetic
susceptibility to weight gain during DCCT might be a
marker of worsening atherosclerosis in the intensive
therapy-received subjects during follow-up in EDIC.
Furthermore, a follow-up study of United Kingdom Pro-
spective Diabetes Study (UKPDS), called UKPDS80, has
also shown that benefits of an intensive therapy in patients
with type 2 diabetes are sustained after the cessation of
the trial [20]. In this study, despite an early loss of gly-
cemic differences between intensive and conventional
therapy, a continued reduction in microvascular risk and
emergent risk reductions for myocardial infarction and
death from any cause were observed during 10 years of
post-trial follow-up [20]. These findings demonstrate that
so-called ‘metabolic memory’, in other words, ‘hypergly-
cemic curse’ may cause chronic abnormalities in diabetic
vessels that are not easily reversed, even by subsequent,
relatively good control of blood glucose, thus suggesting a
long-term beneficial influence of early metabolic control,
that is, legacy effect, on the risk of diabetic retinopathy,
nephropathy, CVD and death in both type 1 and type 2
diabetic patients. Chronic persistent hyperglycemia is a
major initiator of vascular complications of diabetes [2,3].
Various hyperglycemia-elicited metabolic and hemodyna-
mic derangements such as increased formation of AGEs,
enhanced production of reactive oxygen species (ROS)
and activation of the renin-angiotensin system (RAS) and
protein kinase C have been proposed to contribute to
the characteristic histopathological changes within the
diabetic vessels [2,3,21,22]. The metabolic memory is
linked not only to AGEs-RAGE axis but also to some
other pathways [23-26]. Indeed, activation of p66shc
adaptor protein is part of a signal transduction pathway
relevant to hyperglycemia vascular damage [23], and
p66shc oxidizes cytochrome C and generates ROS in
response to stress signals through a protein kinase C-
dependent pathway [24]. Moreover, recent finding has
highlighted that immunization with AGEs inhibits
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null mice [25], thus suggesting the involvement of specific
humoral and cell-mediated immune responses in diabetic
macroangiopathy. Further, AGEs have also been shown to
induce cardiomyocyte autophagy by, at least in part, inhi-
biting the phosphatidylinositol 3-phosphate kinase/Akt/
mammalian target of rapamycin pathway via RAGE [26].
Since these pathways are interrelated with each other, and
therefore, it remains unclear which molecular pathway
is the most crucial one for causing vascular damage in
diabetes. However, the biochemical nature and mode of
action of AGEs are most compatible with the concept
of ‘metabolic memory’ [27-31].
Activation of the AGEs-RAGE axis and metabolic memory
AGEs are formed by the Maillard process, a non-
enzymatic reaction between reducing sugars and the
amino groups of proteins, lipids and nucleic acids that
contributes to the aging of macromolecules [27-31].
Under hyperglycemic and/or oxidative stress conditions,
this process begins with the conversion of reversible Schiff
base adducts to more stable, covalently-bound Amadori
rearrangement products [27-31]. Over the course of days to
weeks, these Amadori products undergo further rearrange-
ment reactions to form the irreversibly-crosslinked moieties
termed AGEs. About 10% of Amadori products could move
to the irreversible process [32]. The formation and accumu-
lation of AGEs have been known to progress in a normal
aging process and at an accelerated rate under diabetes
[27-31]. In addition, AGEs are slowly degraded and remain
for a long time in diabetic vessels even after glycemic con-
trol has been improved [33,34]. Indeed, tissue accumulation
levels of pentosidine have persisted for long periods of time
in patients after kidney or kidney-pancreas transplantation,
despite consistent decreases in plasma levels of pentosidine
[34]. These observations indicate that formation and accu-
mulation of AGEs may continue in diabetic and/or renal
failure patients after successful treatment of blood glucose,
kidney or kidney-pancreas transplantation.
Non-enzymatic glycation and cross-linking of proteins
such as collagen impair its structural integrity and func-
tion [27-31]. In addition, numerous studies have reported
that AGEs and RAGE interaction elicit oxidative stress
generation in various types of cells and subsequently evoke
proliferative, inflammatory, thrombogenic and fibrotic
reactions, thereby playing an important role in the devel-
opment and progression of diabetes-associated disorders
such as diabetic microangiopathy, atherosclerotic cardio-
vascular diseases, Alzheimer’s disease and osteoporosis
[8,9,22,35-40]. Moreover, AGEs are reported to up-
regulate RAGE expression and induce sustained activa-
tion of nuclear factor-κB (NF-κB) [41-43]. Therefore, it
is conceivable that the AGEs-RAGE-induced oxidative
stress generation further potentiates the formation andaccumulation of AGEs and subsequent RAGE overexpres-
sion [41-48]. So, besides the irreversible nature of AGEs,
the positive feedback loops between AGEs and RAGE-
downstream pathways could make a vicious cycle, thus
providing a mechanistic basis for understanding why there
could exist the phenomenon of ‘metabolic memory’ in
vascular complications in diabetes.
Diet or smoking is a major environmental source of
AGEs in humans [49-53]. About 10% of exogenously
derived AGEs were absorbed, two-thirds of which remained
in the body [49-53]. So, overintake of food-derived AGEs or
smoking could increase circulating and tissue accumulation
levels of AGEs in non-diabetic individuals [49-53]. Former
smokers remain at an increased risk for developing lung
cancer and CVD even years after they stop smoking [53].
The possible reason why it had the interesting analogy to
the phenomenon of metabolic memory is that smoking-
derived AGEs may have carry-over effects on the devel-
opment and progression of lung cancer [53]. Recent
epidemiological studies have shown that the incidence
of cancers, including lung cancer is increased in diabetic
patients, especially poorly controlled diabetes [4]. Fur-
thermore, we have very recently found that even after
adjusting for potential confounding risk factors, serum
levels of AGEs could predict the risk of rectal cancer in
an European Prospective Investigation into Cancer and
Nutrition Cohort (unpublished data). Therefore, accu-
mulation of endogenously and/or exogenously derived
AGEs might partly explain the increased risk of various
cancers in diabetes.
Food-derived AGEs have been shown to promote the
aging-associated tissue damage as well [49-52]. Nutrient
composition, temperature and method of cooking can
affect the formation of AGEs in foods; fats or meat-
derived products processed by high heat such as broil-
ing, frying and oven-roasting contain more AGEs than
carbohydrates boiled for longer periods [49-52]. Moreover,
isocaloric restriction of dietary AGEs has been shown
to decrease circulating AGEs levels and inflammatory
biomarkers, improve endothelial dysfunction and restore
the decreased levels of sirtuin 1, an anti-aging molecule
in diabetic patients [54,55]. In addition, AGEs-, but not
calorie-restricted foods can expand lifespan in mice,
while calorie-, but not AGEs-restricted diets can not [56].
These observations suggest that restriction of food-derived
AGEs rather than calorie itself might be a therapeutic target
for anti-aging medicine. Taken together, blockade of the
AGEs-RAGE axis might be a novel therapeutic target for
slowing down the aging process and preventing diabetes-
associated disorders.
Incretins and DPP-4
Incretins such as GLP-1 and GIP are gut hormones se-
creted from L and K cells in the intestine in response to
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augment glucose-induced insulin release from pancreatic
β-cells, suppresses glucagon secretion, and slows gastric
emptying [57,58], incretins have been proposed as a
potential therapeutic target for the treatment of patients
with diabetes. However, native GLP-1 and GIP have a
very short half-life because they are rapidly degraded
and inactivated by proteolytic enzyme, DPP-4 [59,60], and
GIP is also recognized as an obesity-promoting factor in
rats fed a high-fat diet [61]. Therefore, at present, DPP-4
inhibitors and/or DPP-4-resistant GLP-1 analogues rather
than native GLP-1 are clinically used as a GLP-1-based
medicine for the treatment of diabetic subjects.
The biological actions of GLP-1 on pancreatic cells are
mainly mediated by high-affinity GLP-1 receptor (GLP-1R)
[57]. In addition, GLP-1R is shown to exist in extra-
pancreatic tissues, including brain, peripheral nervous
system, kidney, heart and vasculature [62,63]. Further-
more, recently, DPP-4 has been shown to cleave multiple
peptides, and blockade of DPP-4 could exert diverse
biological actions in a variety of cells and tissues [64,65].
These observations suggest that DPP-4 inhibitors could
act on cardiovascular, renal-retinal and nervous sys-
tems, and bone in both GLP-1-dependent and GLP-1-
independent manners. Therefore, in the following section,
we review the crosstalk between AGEs-RAGE axis and
DPP-4-incretin system in the development and progres-
sion of diabetes-associated disorders.
Crosstalk between AGEs-RAGE axis and DPP-4-incretin
system
1) Atherosclerotic CVD
Impaired endothelial cell (EC) growth and enhanced
EC apoptosis are postulated to play a central role in
the pathogenesis of early phase of atherosclerosis
[66]. Atherogenic properties of AGEs could be partly
attributed to its pro-apoptotic effects on ECs
[67-69]. Furthermore, recent clinical investigations
implicate the role of AGEs in impaired EC repair in
atherosclerosis [70-73]. Diabetes is associated with
endothelial dysfunction, decreased endothelial
progenitor cells (EPCs) function and mobilization,
which could contribute to accelerated atherosclerosis
and increased risk for CVD in diabetic patients [70].
AGEs enhance apoptosis and suppress migration and
tube formation of late EPCs through the interaction
with RAGE via down-regulation of Akt and
cycloxygenase-2 [71]. AGEs have also been shown
to cause a reduction of length growth and EPC
incorporation into the sprouts in association with
RAGE overexpression and p38 mitogen-activated
protein kinase (MAPK) activation [72]. Moreover,
AGEs-modification of vascular substrates impairvascular repair by inhibiting EPC adhesion, spreading
and migration via glycation of Arg-Gly-Asp motif of
fibronectin [73]. In addition, we have found that
serum levels of AGEs are inversely associated with
number and migratory activity of EPCs in apparently
healthy subjects [74]. Skin autofluorescence, an
established non-invasive measure of tissue AGEs
accumulation, but not serum levels of pentosidine,
was independently associated with low circulating
EPCs in subjects with end-stage renal failure [75].
Since GLP-1 was reported to protect against AGEs-
induced apoptotic cell death of ECs in association with
increased ratio of Bcl-2/Bax, reduced cytochrome C
levels and suppressed caspase-3 and caspase-9 activity
[76], GLP-1 might promote re-endothelialization
following vascular injury, thereby slowing the
development and progression of atherosclerosis.
Indeed, vildagliptin significantly increased GLP-1
levels and reduced vascular senescence in Zucker
diabetic fatty rats [77]. In addition, sitagliptin, an
inhibitor of DPP-4 was reported to increase circulating
EPCs in type 2 diabetic patients with concomitant
up-regulation of stromal-derived factor-1α as well [78].
There is a growing body of evidence, ranging from
in vitro-experiments to pathologic analysis to
epidemiologic studies, that atherosclerosis is
intrinsically an inflammatory disease [79-82].
Pro-inflammatory cytokines such as tumor necrosis
factor-α and interleukin-1 have been shown to
cause endothelial dysfunction, an initial step of
atherosclerosis [79-82]. Furthermore, atherosclerotic
plaques contain numerous inflammatory cells,
particularly macrophages, which could secrete a
variety of growth factors, cytokines and enzymes
and subsequently contribute to the weakening of
the fibrous cap of the plaques, thereby leading to the
development of acute coronary syndromes [82-85].
Binding of AGEs to RAGE results in generation of
intracellular ROS generation and subsequent
activation of the redox-sensitive transcription factor,
NF-κB in vascular wall cells, which could promote a
variety of atherosclerosis/inflammation-related gene
expression such as monocyte chemoattractant
protein-1 (MCP-1), vascular cell adhesion molecule-
1 (VCAM-1), intercellular adhesion molecule-1
(ICAM-1), and plasminogen activator inhibitor-1
(PAI-1) [41-49]. MCP-1 plays an important role in the
early phase of atherosclerosis by initiating monocyte
recruitment to the vessel wall, and its expression is
elevated in human atherosclerotic plaques [86,87].
The selective targeting of CCR2, the receptor for
MCP-1, markedly decreases atheromatous lesion
formation in apolipoprotein E knockout mice [86,87].
One early phase of atherosclerosis involves the firm
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is mainly mediated by ICAM-1 and VCAM-1 [88-90].
Moreover, attenuated fibrinolytic activity due to
increased PAI-1 levels is highly prevalent in diabetic
patients, thus contributing to the increased risk of
atherothrombosis and CVD in these subjects
[91,92]. These observations further suggest the
active participation of AGEs-RAGE axis in accelerated
atherosclerosis in diabetes.
We have found that GLP-1 blocks the AGE-induced
up-regulation of VCAM-1 mRNA levels in human
umbilical vein ECs (HUVECs) by suppressing RAGE
expression and subsequent ROS generation [93].
Since GLP-1R was expressed in HUVECs and that
small interfering RNAs (siRNAs) raised against GLP-
1R inhibited the GLP-1-induced down-regulation of
RAGE mRNA levels, our present study suggests that
GLP-1 could directly act on ECs via GLP-1R and it
might work as an anti-inflammatory agent against
AGEs by reducing RAGE expression [93]. Furthermore,
an analogue of cyclic AMP, 8-Br-cAMP mimicked the
effects of GLP-1 on RAGE gene expression in
HUVECs. We have previously shown that AGEs
decrease the intracellular cyclic AMP levels in ECs and
that cyclic AMP agonists such as dibutyryl cyclic AMP
reduce the AGEs-RAGE-evoked PAI-1 production
[94]. In addition, GIP receptor (GIPR) was also
expression in HUVECs, and GIP, an analogue of cyclic
AMP or an inhibitor of NADPH oxidase inhibited the
AGEs-induced ROS generation in HUVECs [94]. GIP
reduced gene and protein expression of RAGE and
subsequently decreased VCAM-1 and PAI-1 mRNA
levels in AGEs-exposed HUVECs. An anti-oxidant
N-acetylcysteine mimicked the effects of GIP on
HUVECs. Taken together, these findings suggest the
involvement of cyclic AMP in the AGEs signaling
pathways and that AGEs-RAGE-mediated NADPH
oxidase is a molecular target for anti-inflammatory
effects of GLP-1-GLP-1R- or GIP-GIPR-cyclic AMP
axis in AGEs-exposed HUVECs. Vildagliptin treatment
inhibited the increase in AGEs, RAGE and oxidative
stress marker, 8-hydroxydeoxyguanosine levels of
thoracic aorta of obese and type 2 diabetic rats, which
were in association with decreased gene expression of
MCP-1, VCAM-1 and PAI-1 and suppressed activity of
NF-κB [95]. Further, vildagliptin reduced oxidative
stress generation and decreased inflammatory, fibrotic
and thrombogenic gene expression (ICAM-1,
transforming growth factor- β (TGF-β), and PAI-1) in
thoracic aorta of streptozotocin-induced diabetic rats,
although it did not affect blood glucose levels in type 1
diabetic animals [96]. These findings suggest the
glucose-lowering independent beneficial effects of DPP-
4 inhibitors on experimental diabetic macroangiopathy.AGEs formed on the extracellular matrix results in
decreased elasticity of vasculatures, and quench nitric
oxide (NO), which could mediate defective
endothelium-dependent vasodilatation, a surrogate
marker of CVD in diabetes [97,98]. AGEs not only
decreased endothelial NO synthase (eNOS) mRNA
levels in ECs, but also reduced NO bioavailability
by inactivating NO to form peroxynitrite via ROS
generation [99]. We have previously shown that
GLP-1 modestly restores decreased mRNA levels
of eNOS in AGEs-exposed HUVECs, whose effect
was significantly potentiated by the simultaneous
treatment with sitagliptin [100]. GLP-1 infusion has
also been shown to improve endothelial-dependent
vasodilation in patients with type 2 diabetes, but not
healthy subjects [101].
DPP-4 dose-dependently increased ROS generation
and RAGE gene expression in HUVECs, which were
prevented by an inhibitor of DPP-4, linagliptin [47].
Mannose 6-phosphate (M6P) or neutralizing antibody
raised against M6P/insulin-like growth factor II
receptor (M6P/IGF-IIR) completely blocked the
ROS generation in DPP-4-exposed HUVECs, whereas
surface plasmon resonance revealed that DPP-4
bound to M6P/IGF-IIR at the dissociation constant of
3.59 × 10−5 M [47]. AGEs or hydrogen peroxide
increased soluble DPP-4 production released from
HUVECs, which was prevented by N-acetylcysteine,
neutralizing antibody directed against RAGE or
linagliptin [47]. Linagliptin significantly inhibited
the AGE-induced ROS generation, RAGE, ICAM-1
and PAI-1 gene expression in HUVECs [47]. These
findings suggest that the AGEs-RAGE-induced ROS
generation stimulates the release of DPP-4 from ECs,
which could in turn act on ECs directly via the
interaction with M6P/IGF-IIR, further potentiating
the deleterious effects of AGEs. The blockade by
linagliptin of positive feedback loop between AGE-
RAGE axis and DPP-4 might be a novel therapeutic
target for vascular injury in diabetes (Figures 1 and 2).
We have recently found that serum DPP-4 levels are
independently correlated with HbA1c and AGEs in
432 outpatients who did not receive DPP-4 inhibitors
[102]. Furthermore, AGEs enhanced the expression of
DPP-4 in, and its release from cultured proximal
tubular cells, a major cell type that expressed DPP-4
[102,103]. Since serum AGEs levels are positively
correlated with soluble forms of RAGE and VCAM-1
(sRAGE and sVCAM-1) in diabetic patients
[104-106], AGEs might promote the proteolytic
cleavage of plasma membrane-bound proteins such
as RAGE, VCAM-1 and DPP-4. Given the facts
that serum DPP-4 activity is largely associated with
circulating DPP-4 levels [59,107] and that 20% of
Figure 1 Effects of incretins on pancreatic α and β cells.
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alive in the blood pool [108,109], AGEs may impair
the effects of incretins via induction of DPP-4, further
augmenting the formation and accumulation of AGEs,
making a vicious cycle in poorly controlled diabetes
(Figures 1 and 2). The relatively weak clinical benefit
of vildagliptin in patients with a long history of
diabetes could be partly ascribed to DPP-4 induction
evoked by AGEs [110]. In other words, serum AGEs
levels may be a clinical biomarker to identify which
type 2 diabetic patients will respond less to the
treatment with DPP-4 inhibitors.
2) Diabetic cardiomyopathy
Diabetic cardiomyopathy is characterized by early
impairments in cardiac diastolic dysfunction,
accompanied by the development of cardiomyocyte
hypertrophy and myocardial stiffness, which are
independent of coronary artery disease and
hypertension [105-107]. AGEs-RAGE axis plays a role
in the pathogenesis of diabetic cardiomyopathy via
inducing endothelial dysfunction, altering calciumFigure 2 Crosstalk between the AGEs-RAGE axis and DPP-4.handing/contractility, and evoking inflammatory,
fibrotic and pro-apoptotic reactions in the myocardium
[111-113]. Myocardium of 10-week old db/db−/− mice,
a model of diabetes and obesity, exhibited a marked
increase of phosphorylation of AMP-activated protein
kinase and acetyl-CoA carboxylase as well as
membrane expression of fatty acid translocase, thus
suggesting the altered fatty acid metabolism in
cardiomyocytes of these animals [114]. Furthermore,
myocardial fibrosis and increased expression levels of
TGF − β and AGEs were observed in db/db−/− mice
[114]. Sitagliptin improved glucose tolerance and
reduced weight gain in db/db−/− mice, which were
associated with amelioration of these pathological
changes in cardiomyocytes [114]. Exendin-4, a GLP-1R
agonist significantly inhibited hyperglycemia-induced
RAGE expression and apoptosis of cardiomyocytes,
and improved cell viability as well [115].
Hypertension also induces cardiac dysfunction,
calcium dysregulation, and arrhythmogenesis [116].
Sitagliptin imporved cardiac electrophysiological
characteristics and calcium dysregulation in
spontaneous hypertensive rats by reducing RAGE
and angiotensin II type 1 receptor levels via its
anti-inflammatory properties [116].3) Diabetic nephropathy
Diabetic nephropathy is characterized by functional
and structural changes in the glomerulus such as
glomerular hyperfiltration, thickening of glomerular
basement membrane, and an expansion of
extracellular matrix in the mesangial areas [117,118].
It ultimately progresses glomerular sclerosis
associated with an increased urinary excretion rate
of albumin and renal dysfunction [117,118]. In
addition, although characteristic histological changes
of diabetic nephropathy were diffuse and nodular
glomerulosclerosis [119], it has been also recognized
that changes within tubulointerstitium are more
important than glomerulopathy in terms of renal
dysfunction in diabetic nephropathy [120,121].
Engagement of RAGE with the ligand AGEs elicits
oxidative stress generation and resultantly evokes
inflammatory and fibrotic reactions in the kidney
cells, thereby causing progressive alteration in renal
architecture and loss of renal function associated
with tubular injury in diabetes [117,122].
Furthermore, diabetic homozygous RAGE null mice
failed to develop significantly increased mesangial
matrix expansion or thickening of the glomerular
basement membrane [123]. Deletion of RAGE is also
reported to prevent diabetic nephropathy in the
OVE26 type 1 mouse, a model of progressive
glomerulosclerosis and decline of renal function [124].
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expression of vascular endothelial growth factor
(VEGF) in human cultured mesangial cells, a
counterpart of pericytes in the kidney [125].
Mesangial cells occupy a central anatomical
position in the glomerulus, playing crucial roles in
maintaining structure and function of glomerular
capillary tufts [120]. They actually provide
structural support for capillary loops and modulate
glomerular filtration by its smooth muscle activity
[126-128]. Therefore, the AGEs-induced mesangial
apoptosis and dysfunction may contribute in part to
glomerular hyperfiltration, an early renal dysfunction
in diabetes. Antibody directed against VEGF
has been shown to improve hyperfiltration and
albuminuria in experimental diabetic nephropathy,
and urinary VEGF level is correlated with
albuminuria in type 2 diabetic patients, thus
suggesting the pathological role of VEGF in
hyperpermeability and albuminuria in diabetic
nephropathy [129].
AGEs stimulate MCP-1 expression in mesangial cells
as well [124]. Increased MCP-1 expression associated
with monocyte infiltration in mesangium has been
observed in the early phase of diabetic nephropathy
[130]. Plasma MCP-1 level was associated with
albumin excretion rate in patients with type 1
diabetes, a marker of early diabetic nephropathy [131].
Further, urinary MCP-1/creatinine ratios in type 2
diabetic patients with microalbuminuria were much
higher than those in normal controls, and intensive
insulin treatment significantly decreased the urinary
MCP-1/creatinine ratios [132]. Moreover, selective
targeting of MCP-1, was shown to markedly
decrease albuminuria, renal injury and fibrosis in
streptozotocin-induced diabetic nephropathy [133].
These observations suggest that AGEs accumulation
in the glomeruli could be implicated in inflammatory
and fibrogenic reactions in diabetic nephropathy as
well via promoting the secretion of MCP-1 by
mesangial cells.
GLP-1R is expressed in mesangial cells and proximal
tubular cells [103,134,135]. GLP-1 suppresses RAGE
gene and protein expression and subsequently inhibits
the AGEs-induced ROS generation and MCP-1
expression in human cultured mesangial cells [136].
siRNAs directed against GLP-1R reduced GLP-1R
levels and inhibited the suppressive effects of GLP-1
on RAGE mRNA levels in mesangial cells [136]. In
addition, as the case in HUVECs, an analogue of
cAMP, 8-bromo-cAMP mimicked the effects of
GLP-1 on RAGE gene expression, ROS generation
and MCP-1 mRNA levels in mesangial cells.
These findings suggest that GLP-1 could inhibit theharmful effects of AGEs-RAGE axis on mesangial
cells via GLP-1R-mediated cAMP elevation.
NO is a multifunctional molecule critical to a number
of physiological and pathological processes in humans
[136,137]. NO not only inhibits inflammatory-
proliferative reactions in vascular wall cells and
kidney, but also exerts anti-thrombogenic and EC
protective properties in vivo [136,137]. Therefore,
impaired production and/or bioavailability of NO are
considered to play a role in vascular complications in
diabetes such as diabetic nephropathy and CVD
[136-139]. Indeed, circulating level of asymmetric
dimethylarginine (ADMA), an endogenous NO
synthase inhibitor is increased in early diabetic
nephropathy in type 1 diabetes and associated with
future cardiovascular events in these subjects [140].
Furthermore, serum levels of AGEs were positively
associated with sRAGE and ADMA in patients with
chronic kidney disease [141]. Plasma ADMA levels
were positively associated with serum AGEs level
and inversely correlated with endothelial function
determined by flow-mediated vasodilatation [142],
thus suggesting the active involvement of AGEs-
RAGE system in the elevated levels of ADMA in
humans. We have recently found that GLP-1 inhibits
the AGEs-induced RAGE gene expression, ROS
generation and gene expression of protein arginine
methyltransfetase-1 (PRMT-1), a rate-limiting enzyme
for ADMA generation and subsequently reduces
ADMA levels in cultured human proximal tubular
cells, all of which were blocked by siRNAs raised
against GLP-1R. [135]. In addition, neutralizing
antibody raised against RAGE or N-acetylcysteine
inhibited the AGEs-induced tubular cell gene
expression of PRMT-1. Furthemore, continuous
intraperitoneal infusion of GLP-1 analogue, exendin-4
inhibited renal RAGE gene expression, reduced urinary
excretion level of 8-hydroxy-2’-deoxyguanosine
(8-OHdG), an oxidative stress marker, decreased
PRMT-1 mRNA levels and ADMA generation in the
kidney of type 1 diabetic animals, in association with
improvement of glomerular hypertrophy, macrophage
infiltration into the glomeruli, and glomerular and
tubulointerstitial fibrosis [135]. These observations
suggest that RAGE gene suppression in tubular
cells could be a central mechanism by which
GLP-1 inhibited ADMA levels in the kidney of
early phase of experimental diabetic nephropathy.
AGEs decreased mRNA levels of dimethylarginine
dimethylaminohydrolase-II, a responsible enzyme for
ADMA degradation and suppressed its enzymatic
activity, and resultantly increased ADMA levels in
HUVECs, all of which were completely blocked by an
anti-oxidant, N-acetylcysteine [142].
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angiotensin system plays a role in diabetic nephropathy
[143,144]. We have found that GLP-1 blocked the
angiotensin II-induced superoxide generation, NF-κB
activation, up-regulation of mRNA levels of ICAM-1
and PAI-1 in mesangial cells, all of which were
prevented by the treatments with H-89, an inhibitor
of protein kinase A [145], thus suggesting that GLP-1
could block the angiotensin II-induced mesangial
cell injury by inhibiting superoxide-mediated NF-κB
activation via protein kinase A pathway [145].
Chronic hyperglycaemia induces a significant increase
in DPP-4 activity in type 1 and type 2 diabetes [146].
In accordance with the observation, we have found
that serum levels of DPP-4 are significantly elevated in
streptozotocin-induced diabetic rats compared with
control rats [147]. Although linagliptin treatment for
2 weeks did not improve hyperglycemia in diabetic
rats, linagliptin significantly reduced AGEs levels,
RAGE gene expression and 8-OHdG in the kidney
of diabetic rats [147]. Furthermore, linagliptin
significantly reduced albuminuria, renal ICAM-1
mRNA levels and lymphocyte infiltration into the
glomeruli of diabetic rats [147]. The findings have
extended our previous observations showing that
linagliptin blocked the crosstalk between DPP-4 and
AGEs-RAGE axis in ECs [47]. Linagliptin could exert
beneficial effects on diabetic nephropathy partly by
blocking the AGEs-RAGE-evoked oxidative stress
generation in the kidney of streptozotocin-induced
diabetic rats. Furthermore, we have very recently found
that linagliptin contains xanthine scaffold structure,
which could inhibit xanthine oxidase activity in vitro
and reduce uric acid levels in type 2 diabetic patients
[148,149]. The anti-oxidative unique properties of this
drug might also be involved in the blockade of vicious
cycle between ROS generation and RAGE gene
induction in diabetic nephropathy. Moreover, we
have found that DPP-4 inhibitor alogliptin treatment
blocks the AGEs-RAGE axis and resultantly reduces
albuminuria in type 2 diabetes patients [150].
4) Diabetic retinopathy
We have previously shown that vildagliptin
treatment for 10 weeks prevented the increase in
body weight and decreased average fasting blood
glucose in OLETF rats, an animal model of type 2
diabetes with obesity [151]. Further, vildagliptin
treatment was found to completely inhibit the increase
in angiogenic, inflammatory and thrombogenic gene
expression (VEGF, ICAM-1 and PAI-1) in the retinas
of OLETF rats [151]. Exendin-4 and GLP-1 decreased
RAGE levels in AGEs-exposed human retinal pigment
epithelial cells and made these cells more resistant to
harmful effects of AGEs, leading to suppression ofICAM-1 and VCAM-1 levels [152], thus suggesting
the clinical utility of DPP-4 inhibitors and/or
GLP-1-based medicine for the treatment of obese
type 2 diabetes, including diabetic retinopathy.
The effects of DPP-4 inhibition on microvascular
complications were recently thoroughly described by
Avogaro [153]. Experimental findings and preliminary
clinical data suggest that DPP-4 inhibition, in addition
to improving metabolic control, have the potential to
interfere with the onset and progression of diabetic
microangiopathy [153].
5) Pancreatic β-cell dysfunction
In streptozotocin-induced diabetic rats, a novel
long-acting DPP-4 inhibitor, PKF-275-055 at 3, and
10mg/kg significantly reduced glucose excursion
during the oral glucose tolerance test, with increases
in plasma insulin and active GLP-1 levels as well as
decrease in plasma DPP-4 activity [154]. Furthermore,
PKF-275-055 significantly inhibited glycated
hemoglobin, insulin resistance, gastric emptying and
small intestinal transit rates, which were associated
with pancreatic β-cell regeneration and decreased
apoptosis [154]. In addition, GLP-1 protected beta
cell against AGEs-induced apoptosis and necrosis
[155]. GLP-1 restored the redox balance, improved
the responsiveness to glucose, and attenuated the
AGEs-induced RAGE expression pancreatic islet cell
line HIT-T 15 [155]. Moreover, GLP-1 restored Nrf2
levels in HIT-T 15 cells and subsequently decreased
the susceptibility of β-cells to oxidative stress, which
could lead to improvement of insulin synthesis in
association with increased expression of MafA and
PDX-1, two transcriptional factors that activates
insulin gene promoter [156]. Taken together, these
findings provide evidence that long-acting DPP-4
inhibitors and/or GLP-1 could protect pancreatic
β-cells from the deleterious effects of AGEs.Conclusions
As mentioned above, there is a crosstalk between the
AGEs-RAGE axis and DPP-4-incretin system in the
pathogenesis of diabetes-associated disorders [58,157].
Further longitudinal study is needed to clarify whether
DPP-4 inhibitors and/or GLP-1-based therapies could
prevent the development and progression of devastating
complications of diabetes.
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